Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo + olanzapine Clear all
Completed Phase 3 Interventional

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

NCT00088478
View directory record Official record
Conditions
Schizophrenia
Interventions
Intramuscular Olanzapine Depot, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
34
States / cities
National City, California • Orange, California • Rosemead, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Sep 25, 2026, 4:32 PM EDT
Withdrawn Not applicable Interventional

Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine

NCT00934908
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Green Tea, Placebo
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Modafinil on Olanzapine Weight Gain

NCT00636896
View directory record Official record
Conditions
Weight Gain
Interventions
Olanzapine plus modafinil, Olanzapine plus placebo
Drug
Lead sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2008 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
View directory record Official record
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095
View directory record Official record
Conditions
Bipolar Disorder, Weight Gain
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2 Interventional

Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

NCT00678457
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Ondansetron, Olanzapine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 25, 2026, 4:32 PM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

NCT01234779
View directory record Official record
Conditions
Schizophrenia
Interventions
bitopertin [RO4917838], olanzapine, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Short Term Rescue Study of Olanzapine

NCT00186017
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine/Zyprexa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

Olanzapine in Patients With Borderline Personality Disorder

NCT00091650
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Olanzapine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
15 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
9
States / cities
Atlanta, Georgia • Marietta, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

NCT00402324
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
olanzapine, placebo, divalproex
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorlilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCT00235352
View directory record Official record
Conditions
Schizophrenia
Interventions
CX516 (Ampakine)
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

NCT02708394
View directory record Official record
Conditions
Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
Interventions
olanzapine, placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

NCT00051298
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Little Rock, Arkansas • Cerritos, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

NCT01920802
View directory record Official record
Conditions
Healthy
Interventions
olanzapine, iloperidone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 25, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 25, 2026, 4:32 PM EDT